Global distribution and characteristics of pneumococcal serotypes in adults.

IF 3.5 4区医学 Q2 BIOTECHNOLOGY & APPLIED MICROBIOLOGY Human Vaccines & Immunotherapeutics Pub Date : 2025-12-01 Epub Date: 2025-02-27 DOI:10.1080/21645515.2025.2469424

Haruka Maeda, Konosuke Morimoto

{"title":"Global distribution and characteristics of pneumococcal serotypes in adults.","authors":"Haruka Maeda, Konosuke Morimoto","doi":"10.1080/21645515.2025.2469424","DOIUrl":null,"url":null,"abstract":"<p><p>The introduction of pneumococcal conjugate vaccines (PCVs) into pediatric national immunization programs (NIP) has significantly reduced invasive pneumococcal diseases and pneumococcal pneumonia caused by PCV serotypes in adults due to herd immunity. However, diseases caused by PCV13 serotypes persist, mainly serotype 3, known for its severity. With the reduction in PCV13 serotypes, diseases caused by non-PCV13 serotypes increased. Residual and emerging serotypes vary regionally; serotype 8 in Europe and South Africa, and serotype 4 in the US and Canada. PCV20 and PCV21 were recently developed, which can prevent residual and emerging pneumococcal diseases where herd immunity is well-established. In countries that have not introduced PCV into pediatric NIP, the pneumococcal disease burden due to PCV serotypes is still marked. Given that serotype distribution varies by region and evolves over time, this review aimed to discuss serotype distribution and disease severity in adults across countries to support future pneumococcal vaccine strategies.</p>","PeriodicalId":49067,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":"21 1","pages":"2469424"},"PeriodicalIF":3.5000,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11869777/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Human Vaccines & Immunotherapeutics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/21645515.2025.2469424","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/2/27 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

The introduction of pneumococcal conjugate vaccines (PCVs) into pediatric national immunization programs (NIP) has significantly reduced invasive pneumococcal diseases and pneumococcal pneumonia caused by PCV serotypes in adults due to herd immunity. However, diseases caused by PCV13 serotypes persist, mainly serotype 3, known for its severity. With the reduction in PCV13 serotypes, diseases caused by non-PCV13 serotypes increased. Residual and emerging serotypes vary regionally; serotype 8 in Europe and South Africa, and serotype 4 in the US and Canada. PCV20 and PCV21 were recently developed, which can prevent residual and emerging pneumococcal diseases where herd immunity is well-established. In countries that have not introduced PCV into pediatric NIP, the pneumococcal disease burden due to PCV serotypes is still marked. Given that serotype distribution varies by region and evolves over time, this review aimed to discuss serotype distribution and disease severity in adults across countries to support future pneumococcal vaccine strategies.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

成人肺炎球菌血清型的全球分布和特征。

将肺炎球菌结合疫苗（PCVs）引入儿童国家免疫规划（NIP），显著减少了侵袭性肺炎球菌疾病和由PCV血清型引起的成人肺炎球菌肺炎，这是由于群体免疫。然而，由PCV13血清型引起的疾病仍然存在，主要是血清3型，以其严重程度而闻名。随着PCV13血清型的减少，非PCV13血清型引起的疾病增加。残留和新出现的血清型因地区而异；欧洲和南非为血清8型，美国和加拿大为血清4型。PCV20和PCV21是最近开发的，可在群体免疫已建立的地方预防残余和新发肺炎球菌疾病。在尚未将PCV引入儿科NIP的国家，PCV血清型引起的肺炎球菌疾病负担仍然很明显。鉴于血清型分布因地区和时间而异，本综述旨在讨论各国成人血清型分布和疾病严重程度，以支持未来的肺炎球菌疫苗策略。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Human Vaccines & Immunotherapeutics BIOTECHNOLOGY & APPLIED MICROBIOLOGY-IMMUNOLOGY

CiteScore

7.90

自引率

8.30%

发文量

489

审稿时长

3-6 weeks

期刊介绍： (formerly Human Vaccines; issn 1554-8619) Vaccine research and development is extending its reach beyond the prevention of bacterial or viral diseases. There are experimental vaccines for immunotherapeutic purposes and for applications outside of infectious diseases, in diverse fields such as cancer, autoimmunity, allergy, Alzheimer’s and addiction. Many of these vaccines and immunotherapeutics should become available in the next two decades, with consequent benefit for human health. Continued advancement in this field will benefit from a forum that can (A) help to promote interest by keeping investigators updated, and (B) enable an exchange of ideas regarding the latest progress in the many topics pertaining to vaccines and immunotherapeutics. Human Vaccines & Immunotherapeutics provides such a forum. It is published monthly in a format that is accessible to a wide international audience in the academic, industrial and public sectors.